Ida Vogel

List of Publications by Year
in descending order

147 papers	3,544 citations	147801 31 h-index	182427 51 g-index
169 all docs	169 docs citations	169 times ranked	4877 citing authors

#	Article	IF	Citations
1	A flow from screening to diagnostics. , 2022, , 3-20.		0
2	The importance of information and support following a suspected secondâ€trimester anomaly that is later discarded: A qualitative study of women's experiences. Acta Obstetricia Et Gynecologica Scandinavica, 2022, 101, 94-101.	2.8	3
3	Assessing womenâ€™s preferences towards tests that may reveal uncertain results from prenatal genomic testing: Development of attributes for a discrete choice experiment, using a mixed-methods design. PLoS ONE, 2022, 17, e0261898.	2.5	4
4	Cell-Based NIPT Detects 47,XXY Genotype in a Twin Pregnancy. Frontiers in Genetics, 2022, 13, 842092.	2.3	2
5	Factors that impact on women's decisionâ€making around prenatal genomic tests: An international discrete choice survey. Prenatal Diagnosis, 2022, 42, 934-946.	2.3	5
6	Cellâ€based nonâ€invasive prenatal diagnosis in a pregnancy at risk of cystic fibrosis. Prenatal Diagnosis, 2021, 41, 234-240.	2.3	9
7	Increased prenatal detection of 22q11.2 deletion and 22q11.2 duplication after introduction of nationwide prenatal screening for trisomy 21, trisomy 13, and trisomy 18. Prenatal Diagnosis, 2021, 41, 218-225.	2.3	2
8	Trisomy 8 mosaicism in the placenta: A Danish cohort study of 37 cases and a literature review. Prenatal Diagnosis, 2021, 41, 409-421.	2.3	3
9	National data on the early clinical use of nonâ€invasive prenatal testing in public and private healthcare in Denmark 2013â€“2017. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 884-892.	2.8	11
10	Clinical and genetic evaluation of Danish patients with pycnodysostosis. European Journal of Medical Genetics, 2021, 64, 104135.	1.3	12
11	Dealing with uncertain results from chromosomal microarray and exome sequencing in the prenatal setting: An international crossâ€sectional study with healthcare professionals. Prenatal Diagnosis, 2021, 41, 720-732.	2.3	13
12	A novel homozygous variant in C1QBP causes severe IUGR , edema, and cardiomyopathy in two fetuses. JIMD Reports, 2021, 59, 20-25.	1.5	3
13	Cell-based non-invasive prenatal testing for monogenic disorders: confirmation of unaffected fetuses following preimplantation genetic testing. Journal of Assisted Reproduction and Genetics, 2021, 38, 1959-1970.	2.5	6
14	How are uncertain prenatal genetic results perceived and managed twoÂyears after they were received? A qualitative interview study. Journal of Genetic Counseling, 2021, 30, 1191-1202.	1.6	2
15	Mosaicism for copy number variations in the placenta is even more difficult to interpret than mosaicism for whole chromosome aneuploidy. Prenatal Diagnosis, 2021, 41, 668-680.	2.3	6
16	â€œI had to think: This is not a child.â€•A qualitative exploration of how women/couples articulate their relation to the fetus/child following termination of a wanted pregnancy due to Down syndrome. Sexual and Reproductive Healthcare, 2021, 28, 100606.	1.2	1
17	How to deal with uncertainty in prenatal genomics: A systematic review of guidelines and policies. Clinical Genetics, 2021, 100, 647-658.	2.0	15
18	Screening for Fetal Aneuploidy and Sex Chromosomal Anomalies in a Pregnant Woman With Mosaicism for Turner Syndromeâ€”Applications and Advantages of Cell-Based NIPT. Frontiers in Genetics, 2021, 12, 741752.	2.3	9

#	Article	IF	Citations
19	A novel nonsense variant in MED12 associated with malformations in a female fetus. Clinical Case Reports (discontinued), 2021, 9, e05124.	0.5	1
20	Trends in Non-invasive Prenatal Screening and Invasive Testing in Denmark (2000â€“2019) and Israel (2011â€“2019). Frontiers in Medicine, 2021, 8, 768997.	2.6	4
21	Fetal Costello syndrome: description of phenotype of HRAS exon 1 mutations. Ultrasound in Obstetrics and Gynecology, 2020, 55, 274-275.	1.7	2
22	Phenotypic presentations of Hajdu-Cheney syndrome according to age â€“ 5 distinct clinical presentations. European Journal of Medical Genetics, 2020, 63, 103650.	1.3	6
23	Placental mosaicism in the era of chromosomal microarrays. European Journal of Medical Genetics, 2020, 63, 103778.	1.3	7
24	â€œThis is the child we were givenâ€: A qualitative study of Danish parentsâ€™ experiences of a prenatal Down syndrome diagnosis and their decision to continue the pregnancy. Sexual and Reproductive Healthcare, 2020, 23, 100480.	1.2	13
25	Prevalence of mosaicism in uncultured chorionic villus samples after chromosomal microarray and clinical outcome in pregnancies affected by confined placental mosaicism. Prenatal Diagnosis, 2020, 40, 244-259.	2.3	23
26	First trimester biomarkers for prediction of gestational diabetes mellitus. Placenta, 2020, 101, 80-89.	1.5	27
27	Cellâ€based noninvasive prenatal testing (cbNIPT) detects pathogenic copy number variations. Clinical Case Reports (discontinued), 2020, 8, 2561-2567.	0.5	8
28	Do fetal extravillous trophoblasts circulate in maternal blood postpartum?. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 751-756.	2.8	12
29	How do geneticists and prospective parents interpret and negotiate an uncertain prenatal genetic result? An analysis of clinical interactions. Journal of Genetic Counseling, 2020, 29, 1221-1233.	1.6	7
30	Personalized medicine for the embryo and the fetus â€“ Options in modern genetics influence preconception and prenatal choices. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 689-691.	2.8	4
31	Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 722-730.	2.8	121
32	The Number of Circulating Fetal Extravillous Trophoblasts Varies from Gestational Week 6 to 20. Reproductive Sciences, 2020, 27, 2170-2174.	2.5	14
33	"It's probably nothing, butâ€¦" Couples' experiences of pregnancy following an uncertain prenatal genetic result. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 791-801.	2.8	18
34	Implementation of exome sequencing in fetal diagnosticsâ€”Data and experiences from a tertiary center in Denmark. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 783-790.	2.8	33
35	Nuchal translucency of 3.0â€3.4Âmm an indication for NIPT or microarray? Cohort analysis and literature review. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 765-774.	2.8	34
36	New tight junction protein 2 variant causing progressive familial intrahepatic cholestasis type 4 in adults: A case report. World Journal of Gastroenterology, 2020, 26, 550-561.	3.3	18

#	Article	IF	Citations
37	Is MED13L-related intellectual disability a recognizable syndrome?. European Journal of Medical Genetics, 2019, 62, 129-136.	1.3	21
38	Denmarkâ€™s exemplary gender balance trips up in science. Nature, 2019, 572, 178-178.	27.8	0
39	Secondâ€trimester fetal head circumference in more than 350 000 pregnancies: Outcome and suggestion for sexâ€dependent cutoffs for small heads. Prenatal Diagnosis, 2019, 39, 910-920.	2.3	5
40	Heterozygous Variants in KMT2E Cause a Spectrum of Neurodevelopmental Disorders and Epilepsy. American Journal of Human Genetics, 2019, 104, 1210-1222.	6.2	56
41	Receiving a prenatal diagnosis of Down syndrome by phone: a qualitative study of the experiences of pregnant couples. BMJ Open, 2019, 9, e026825.	1.9	2
42	Does Maternal Body Mass Index Affect the Quantity of Circulating Fetal Cells Available to Use for Cell-Based Noninvasive Prenatal Test in High-Risk Pregnancies?. Fetal Diagnosis and Therapy, 2019, 45, 353-356.	1.4	20
43	Population-Based Screening for Trisomies and Atypical Chromosomal Abnormalities: Improving Efficacy using the Combined First Trimester Screening Algorithm as well as Individual Risk Parameters. Fetal Diagnosis and Therapy, 2019, 45, 424-429.	1.4	13
44	Is carriership of a balanced translocation or inversion an indication for non-invasive prenatal testing?. Expert Review of Molecular Diagnostics, 2018, 18, 477-479.	3.1	5
45	Prenatal screening for atypical chromosomal abnormalities: past or future?. Ultrasound in Obstetrics and Gynecology, 2018, 51, 434-435.	1.7	5
46	Unexplained cholestasis in adults and adolescents: diagnostic benefit of genetic examination. Scandinavian Journal of Gastroenterology, 2018, 53, 305-311.	1.5	15
47	Case of successful IVF treatment of an oligospermic male with 46,XX/46,XY chimerism. Journal of Assisted Reproduction and Genetics, 2018, 35, 1325-1328.	2.5	15
48	Chromosomal microarray as primary diagnostic genomic tool for pregnancies at increased risk within a populationâ€based combined firstâ€trimester screening program. Ultrasound in Obstetrics and Gynecology, 2018, 51, 480-486.	1.7	46
49	National screening guidelines and developments in prenatal diagnoses and live births of Down syndrome in 1973â€“2016 in Denmark. Acta Obstetricia Et Gynecologica Scandinavica, 2018, 97, 195-203.	2.8	41
50	Algorithm for sorting chromosomal aberration data. Ultrasound in Obstetrics and Gynecology, 2018, 51, 557-558.	1.7	0
51	Danish Sonographersâ€™ Experiences of the Introduction of â€œModerate Riskâ€• in Prenatal Screening for Down Syndrome. Journal of Pregnancy, 2018, 2018, 1-7.	2.4	1
52	Novel <scp>TRPV</scp>4 variant causes a severe form of metatropic dysplasia. Clinical Case Reports (discontinued), 2018, 6, 1774-1778.	0.5	4
53	Termination of pregnancy following a prenatal diagnosis of Down syndrome: A qualitative study of the decisionâ€making process of pregnant couples. Acta Obstetricia Et Gynecologica Scandinavica, 2018, 97, 1228-1236.	2.8	34
54	Ultrasound in Prenatal Diagnostics and Its Impact on the Epidemiology of Spina Bifida in a National Cohort from Denmark with a Comparison to Sweden. BioMed Research International, 2018, 2018, 1-8.	1.9	18

#	Article	IF	Citations
55	Isochromosome 21q is overrepresented among false-negative cell-free DNA prenatal screening results involving Down syndrome. European Journal of Human Genetics, 2018, 26, 1490-1496.	2.8	16
56	Preferences for prenatal testing among pregnant women, partners and health professionals. Danish Medical Journal, 2018, 65, .	0.5	4
57	Confirmation of CAGSSS syndrome as a distinct entity in a Danish patient with a novel homozygous mutation in IARS2. American Journal of Medical Genetics, Part A, 2017, 173, 1102-1108.	1.2	17
58	Fetal cells in maternal blood for prenatal diagnosis: a love story rekindled. Biomarkers in Medicine, 2017, 11, 705-710.	1.4	21
59	Experiences and expectations in the first trimester of pregnancy: a qualitative study. Health Expectations, 2017, 20, 1320-1329.	2.6	23
60	Parental response to severe or lethal prenatal diagnosis: a systematic review of qualitative studies. Prenatal Diagnosis, 2017, 37, 731-743.	2.3	28
61	Metatarsal bony syndactyly in 2 fetuses with Smithâ€Lemliâ€Opitz syndrome: An underâ€recognized part of the clinical spectrum. Clinical Genetics, 2017, 92, 342-343.	2.0	1
62	PBX1haploinsufficiency leads to syndromic congenital anomalies of the kidney and urinary tract (CAKUT) in humans. Journal of Medical Genetics, 2017, 54, 502-510.	3.2	46
63	On the road to replacing invasive testing with cellâ€based NIPT: Five clinical cases with aneuploidies, microduplication, unbalanced structural rearrangement, or mosaicism. Prenatal Diagnosis, 2017, 37, 1120-1124.	2.3	47
64	Novel compound heterozygous mutations in TELO2 in a patient with severe expression of You-Hoover-Fong syndrome. Molecular Genetics & Genomic Medicine, 2017, 5, 580-584.	1.2	15
65	First reported case of Simpsonâ€“Golabiâ€“Behmel syndrome in a female fetus diagnosed prenatally with chromosomal microarray. Clinical Case Reports (discontinued), 2017, 5, 608-612.	0.5	8
66	Isolated congenital hepatic fibrosis associated with TMEM67 mutations: report of a new genotypeâ€“phenotype relationship. Clinical Case Reports (discontinued), 2017, 5, 1098-1102.	0.5	8
67	Induction of puberty with human chorionic gonadotropin (hCG) followed by reversal of hypogonadotropic hypogonadism in Kallmann syndrome.. Endokrynologia Polska, 2017, 68, 692-696.	1.0	2
68	Nuchal translucency distributions for different chromosomal anomalies in a large unselected population cohort. Prenatal Diagnosis, 2016, 36, 49-55.	2.3	13
69	Towards a new era in fetal medicine in the Nordic countries. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 845-849.	2.8	2
70	Epilepsy and cataplexy in Angelman syndrome. Genotype-phenotype correlations. Research in Developmental Disabilities, 2016, 56, 177-182.	2.2	9
71	Mutations in human C2CD3 cause skeletal dysplasia and provide new insights into phenotypic and cellular consequences of altered C2CD3 function. Scientific Reports, 2016, 6, 24083.	3.3	30
72	Non-invasive prenatal testing offered as part of a combined first-trimester screening program identifies tetrasomy 18p in a high-risk pregnancy. Prenatal Diagnosis, 2016, 36, 1112-1114.	2.3	5

#	Article	IF	Citations
73	Cell-free DNA in pregnancy with choriocarcinoma and coexistent live fetus. Medicine (United States), 2016, 95, e4721.	1.0	6
74	Mechanism of pancreatic and liver malformations in human fetuses with shortâ€rib polydactyly syndrome. Birth Defects Research Part A: Clinical and Molecular Teratology, 2016, 106, 549-562.	1.6	1
75	Disruption of POGZ Is Associated with Intellectual Disability and Autism Spectrum Disorders. American Journal of Human Genetics, 2016, 98, 541-552.	6.2	132
76	Preferences for prenatal tests for Down syndrome: an international comparison of the views of pregnant women and health professionals. European Journal of Human Genetics, 2016, 24, 968-975.	2.8	56
77	The development of hepatic stellate cells in normal and abnormal human fetuses - an immunohistochemical study. Physiological Reports, 2015, 3, e12504.	1.7	4
78	First trimester screening for other trisomies than trisomy 21, 18, and 13. Prenatal Diagnosis, 2015, 35, 612-619.	2.3	25
79	Chromosomal microarray in fetuses with increased nuchal translucency. Ultrasound in Obstetrics and Gynecology, 2015, 45, 95-100.	1.7	49
80	Potential Diagnostic Consequences of Applying Noninvasive Prenatal Testing. Obstetrical and Gynecological Survey, 2014, 69, 321-323.	0.4	1
81	Potential diagnostic consequences of applying nonâ€invasive prenatal testing: populationâ€based study from a country with existing firstâ€trimester screening. Ultrasound in Obstetrics and Gynecology, 2014, 43, 265-271.	1.7	106
82	Eating behavior, prenatal and postnatal growth in Angelman syndrome. Research in Developmental Disabilities, 2014, 35, 2681-2690.	2.2	18
83	Neurodevelopmental outcome in Angelman syndrome: Genotypeâ€“phenotype correlations. Research in Developmental Disabilities, 2014, 35, 1742-1747.	2.2	40
84	PSCC: Sensitive and Reliable Population-Scale Copy Number Variation Detection Method Based on Low Coverage Sequencing. PLoS ONE, 2014, 9, e85096.	2.5	30
85	Diagnostic performance of quantitative fluorescence PCR analysis in high-risk pregnancies after combined first-trimester screening. Danish Medical Journal, 2014, 61, A4964.	0.5	4
86	Prenatal diagnosis: array comparative genomic hybridization in fetuses with abnormal sonographic findings. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 762-768.	2.8	29
87	Phenotype in 18 Danish subjects with genetically verified CHARGE syndrome. Clinical Genetics, 2013, 83, 125-134.	2.0	30
88	Angelman syndrome in Denmark. Birth incidence, genetic findings, and age at diagnosis. American Journal of Medical Genetics, Part A, 2013, 161, 2197-2203.	1.2	76
89	A description of a fetal syndrome associated with HNF1B mutation and a wide intrafamilial disease variability. American Journal of Medical Genetics, Part A, 2013, 161, 3191-3195.	1.2	12
90	Existing data sources for clinical epidemiology: Danish registries for studies of medical genetic diseases. Clinical Epidemiology, 2013, 5, 249.	3.0	30

#	Article	IF	Citations
91	Goblet Cell Carcinoid in a Patient with Neurofibromatosis Type 1: A Rare Combination. Case Reports in Gastrointestinal Medicine, 2012, 2012, 1-3.	0.3	2
92	Cytokines and the Risk of Preterm Delivery in Twin Pregnancies. Obstetrics and Gynecology, 2012, 120, 60-68.	2.4	15
93	Screening performance for trisomy 21 comparing first trimester combined screening and a first trimester contingent screening protocol including ductus venosus and tricuspid flow. Prenatal Diagnosis, 2012, 32, 783-788.	2.3	7
94	Low serum interleukinâ€17 is associated with preterm delivery. Acta Obstetricia Et Gynecologica Scandinavica, 2011, 90, 92-96.	2.8	14
95	Firstâ€trimester screening for trisomy 21 in Denmark: implications for detection and birth rates of trisomy 18 and trisomy 13. Ultrasound in Obstetrics and Gynecology, 2011, 38, 140-144.	1.7	41
96	Identification of submicroscopic chromosomal aberrations in fetuses with increased nuchal translucency and apparently normal karyotype. Ultrasound in Obstetrics and Gynecology, 2011, 38, 314-319.	1.7	102
97	OC01.01: Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo-controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics and Gynecology, 2011, 38, 1-1.	1.7	5
98	OC06.01: Vaginal progesterone and the risk of preterm delivery in highâ€risk twin gestations â€secondary analysis of a placeboâ€controlled randomized trial. Ultrasound in Obstetrics and Gynecology, 2011, 38, 11-11.	1.7	4
99	A BRCA2 mutation incorrectly mapped in the original BRCA2 reference sequence, is a common West Danish founder mutation disrupting mRNA splicing. Breast Cancer Research and Treatment, 2011, 128, 179-185.	2.5	4
100	Ethnic differences in informed decision-making about prenatal screening for Down's syndrome. Journal of Epidemiology and Community Health, 2010, 64, 262-268.	3.7	46
101	Circulating relaxin and cervical length in midpregnancy are independently associated with spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2009, 201, 169.e1-169.e6.	1.3	14
102	Pallisterâ€“Killian syndrome in a girl with mild developmental delay and mosaicism for hexasomy 12p. American Journal of Medical Genetics, Part A, 2009, 149A, 510-514.	1.2	16
103	Firstâ€trimester maternal plasma cytokine levels, preâ€pregnancy body mass index, and spontaneous preterm delivery. Acta Obstetricia Et Gynecologica Scandinavica, 2009, 88, 332-342.	2.8	22
104	Polymorphisms in the promoter region of relaxin-2 and preterm birth: involvement of relaxin in the etiology of preterm birth. In Vivo, 2009, 23, 1005-9.	1.3	5
105	Reference population for international comparisons and time trend surveillance of preterm delivery proportions in three countries. BMC Women's Health, 2008, 8, 16.	2.0	45
106	Testing for 22q11 microdeletion in 146 fetuses with nuchal translucency above the 99th percentile and a normal karyotype. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 1252-1255.	2.8	18
107	Racial disparity in amniotic fluid concentrations of tumor necrosis factor (TNF)-Î± and soluble TNF receptors in spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2008, 198, 533.e1-533.e10.	1.3	50
108	Maternal plasma cytokines in early- and mid-gestation of normal human pregnancy and their association with maternal factors. Journal of Reproductive Immunology, 2008, 77, 152-160.	1.9	80

#	Article	IF	Citations
109	Interleukin-18 and interleukin-12 in maternal serum and spontaneous preterm delivery. Journal of Reproductive Immunology, 2008, 77, 179-185.	1.9	35
110	Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples. Journal of Immunological Methods, 2008, 336, 78-84.	1.4	115
111	Truncation of the Down Syndrome Candidate Gene DYRK1A in Two Unrelated Patients with Microcephaly. American Journal of Human Genetics, 2008, 82, 1165-1170.	6.2	145
112	Increased Bioavailability of TNF-Î± in African Americans During In Vitro Infection: Predisposing Evidence for Immune Imbalance. Placenta, 2007, 28, 946-950.	1.5	20
113	Early second-trimester inflammatory markers and short cervical length and the risk of recurrent preterm birth. Journal of Reproductive Immunology, 2007, 75, 133-140.	1.9	81
114	Midâ€pregnancy maternal plasma levels of interleukin 2, 6, and 12, tumor necrosis factorâ€alpha, interferonâ€gamma, and granulocyteâ€macrophage colonyâ€stimulating factor and spontaneous preterm delivery. Acta Obstetricia Et Gynecologica Scandinavica, 2007, 86, 1103-1110.	2.8	68
115	Chlamydia trachomatis C-complex serovars are a risk factor for preterm birth. In Vivo, 2007, 21, 107-12.	1.3	9
116	Prediction of preterm delivery using changes in serum relaxin in low risk pregnancies. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 128, 113-118.	1.1	19
117	Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study. BMJ: British Medical Journal, 2006, 332, 937-939.	2.3	185
118	Risk factors for bacterial vaginosis in pregnancy: a populationâ€based study on Danish women. Acta Obstetricia Et Gynecologica Scandinavica, 2006, 85, 906-911.	2.8	35
119	The joint effect of vaginalUreaplasma urealyticumand bacterial vaginosis on adverse pregnancy outcomes. Acta Obstetricia Et Gynecologica Scandinavica, 2006, 85, 778-785.	2.8	37
120	Early mid-trimester serum relaxin, soluble CD163, and cervical length in women at high risk for preterm delivery. American Journal of Obstetrics and Gynecology, 2006, 195, 208-214.	1.3	22
121	Multilocus interactions at maternal tumor necrosis factor-Î±, tumor necrosis factor receptors, interleukin-6 and interleukin-6 receptor genes predict spontaneous preterm labor in European-American women. American Journal of Obstetrics and Gynecology, 2006, 194, 1616-1624.	1.3	83
122	Ethnic Differences in Key Candidate Genes for Spontaneous Preterm Birth: TNF-Î± and Its Receptors. Human Heredity, 2006, 62, 107-118.	0.8	53
123	Acquisition and Elimination of Bacterial Vaginosis During Pregnancy: A Danish Population-Based Study. Infectious Diseases in Obstetrics and Gynecology, 2006, 2006, 1-6.	1.5	6
124	Bacterial vaginosis in early pregnancy is associated with low birth weight and small for gestational age, but not with spontaneous preterm birth: A population-based study on Danish women. Journal of Maternal-Fetal and Neonatal Medicine, 2006, 19, 1-7.	1.5	24
125	Preterm delivery in primiparous women at low risk: Preterm birth or delivery? Study authors suggest new terms. BMJ: British Medical Journal, 2006, 332, 1094.2.	2.3	0
126	Preterm delivery predicted by soluble CD163 and CRP in women with symptoms of preterm delivery. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 737-742.	2.3	32

#	Article	IF	Citations
127	Biomarkers for the prediction of preterm delivery. Acta Obstetricia Et Gynecologica Scandinavica, 2005, 84, 516-525.	2.8	88
128	Biomarkers for the prediction of preterm delivery. Acta Obstetricia Et Gynecologica Scandinavica, 2005, 84, 516-525.	2.8	6
129	The Influence of Amphotericin B and Neomycin on the Effect of Human Relaxin-2 on Foetal Membranes and Isolated Myometrium. Basic and Clinical Pharmacology and Toxicology, 2004, 94, 144-150.	2.5	1
130	Insulin-like growth factor binding protein 1 (IGFBP-1) in vaginal fluid in pregnancy. In Vivo, 2004, 18, 37-41.	1.3	9
131	Biphasic effect of relaxin, inhibitable by a collagenase inhibitor, on the strength of human fetal membranes. In Vivo, 2004, 18, 581-4.	1.3	4
132	Albumin in vaginal fluid is a marker of infection in early pregnancy. International Journal of Gynecology and Obstetrics, 2003, 83, 307-308.	2.3	6
133	Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice. Journal of Endocrinology, 2002, 172, 637-643.	2.6	19
134	Title is missing!. Journal of Pediatric Orthopaedics, 2002, 22, 88-91.	1.2	4
135	Serum 17 Î²-Estradiol in Newborn and Neonatal Hip Instability. Journal of Pediatric Orthopaedics, 2002, 22, 88-91.	1.2	17
136	S-relaxin as a predictor of preterm delivery in women with symptoms of preterm labour. BJOG: an International Journal of Obstetrics and Gynaecology, 2002, 109, 977-982.	2.3	25
137	Serum 17 beta-estradiol in newborn and neonatal hip instability. Journal of Pediatric Orthopaedics, 2002, 22, 88-91.	1.2	7
138	Identification of biological/biochemical marker(s) for preterm delivery. Paediatric and Perinatal Epidemiology, 2001, 15, 90-103.	1.7	23
139	Association between raised serum relaxin levels during the eighteenth gestational week and very preterm delivery. American Journal of Obstetrics and Gynecology, 2001, 184, 390-393.	1.3	22
140	Preterm delivery predicted by serum relaxin. , 2001, , 425-428.		0
141	Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes. Kidney International, 1998, 53, 173-180.	5.2	30
142	Title is missing!. Journal of Pediatric Orthopaedics, 1998, 18, 535-537.	1.2	1
143	Serum Relaxin in the Newborn Is Not a Marker of Neonatal Hip Instability. Journal of Pediatric Orthopaedics, 1998, 18, 535-537.	1.2	15
144	Serum relaxin in the newborn is not a marker of neonatal hip instability. Journal of Pediatric Orthopaedics, 1998, 18, 535-7.	1.2	10

#	Article	IF	Citations
145	No effects of human relaxin on the active and passive biomechanical properties of isolated cervical specimens from nonpregnant women. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1997, 73, 183-187.	1.1	7
146	Variations in serum relaxin (hRLXâ€2) concentrations during human pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 1995, 74, 251-256.	2.8	56
147	Relaxin (hRLX-2)-induced weakening of human fetal membranes in vitro. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1994, 57, 123-128.	1.1	24